CanSino Biologics
Tianjin
About CanSino Biologics
CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Total funding: $17.0M
- Last round: Grant (Oct 2024)
- Website: cansinotech.com.cn
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/cansino-biologics-87382 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.